AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03079856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a \~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment.
Study NCT02174146 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-surgical periodontal therapy
Description: supra and subgingival debridement
Study NCT01722656 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Study NCT04397328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine vs placebo (1:1 design) double blind intervention
Study NCT04397328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydroxychloroquine vs placebo (1:1 design) double blind intervention
Study NCT00326248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769 (casopitant)
Study NCT02193113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD001 Injection
Description: A novel plasma kallikrein inhibitor
Study NCT03927404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active vacuum test prosthesis
Description: The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
Study NCT01608841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 100 mg 1# PO qd till disease progression
Study NCT05685056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
Study NCT02641067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
Study NCT04659694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wellness programme provided by Oomph! Wellness company
Description: The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
Study NCT02186704 — intervention group
Intervention type: DEVICE
Intervention: ICD with DX system
Description: Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
Study NCT02342262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EcologicBarrier
Description: multispecies probiotic product, 2x10-9 cfu/gram
Study NCT02342262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar appearance as the probiotic product, but without bacteria
Study NCT00498121 — intervention group
Intervention type: DEVICE
Intervention: PROCALCITONIN LEVEL
Description: measuring PROCALCITONIN LEVEL
Study NCT03628274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) 7 Tesla
Description: An MRI performed as part of the project
Study NCT03628274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) 1,5 Tesla
Description: An MRI performed as part of the care
Study NCT03189901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular management+Levosimendan
Description: Patients are treated with regular management recommended in guidelines and levosimendan.
Study NCT01654809 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: evaluated vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
Study NCT01654809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: evaluated vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
Study NCT01654809 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: imported compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
Study NCT01654809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: imported compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
Study NCT01654809 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: domestic compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
Study NCT01654809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: domestic compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
Study NCT02874027 — intervention group
Intervention type: OTHER
Intervention: The TBI patients with depression
Description: The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
Study NCT01147848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/Vilanterol Inhalation Powder
Description: Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
Study NCT01147848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/salmeterol Inhalation Powder
Description: Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
Study NCT01147848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (1)
Description: Inhalation powder inhaled orally once daily for 24 weeks
Study NCT01147848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (2)
Description: Inhalation powder inhaled orally twice daily for 24 weeks
Study NCT00685737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-MNA
Description: Capsule
Study NCT00685737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT00259207 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary valve insertion
Description: Pulmonary valve insertion
Study NCT00259207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medical surgery hybride
Description: medical surgery hybride
Study NCT03442660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
Study NCT01424280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1440115
Description: Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
Study NCT01424280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching placebo tablets
Study NCT00565799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omentectomy
Description: Removing the omentum
Study NCT00565799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Only LAGB without Omentectomy
Study NCT01759823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation
Description: 20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
Study NCT01759823 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: 5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
Study NCT01759823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC's TRANSPLANTATION
Description: 20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
Study NCT02100306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Feedback 100%
Description: Patients will receive constant auditory feedback across training trials.
Study NCT02100306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Feedback 50% alternate
Description: Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
Study NCT04198675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised EMG Biofeedback Exercise Training Group
Description: Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.
Study NCT04198675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise Training Group
Description: Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence
Study NCT04198675 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Posture Training/Ergonomic Regulations Group
Description: Posture training and ergonomic arrangements in the workplace.
Study NCT02156336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Oral administration, BID; for a maximum of 51 days.
Study NCT02156336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, BID; for a maximum of 51 days.
Study NCT03101085 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: S-equol and Placebo
Description: S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
Study NCT03101085 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo and S-equol
Description: S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
Study NCT00067782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (immediate switch)
Description: Capsules, Oral, 400mg, Once daily, 48 weeks.
Study NCT00067782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (Week 24 switch)
Description: Capsules, Oral, 400mg, Once daily, 48 weeks.
Study NCT02757612 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: laser diode
Description: laser diode
Study NCT02757612 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: laser diode
Description: laser diode
Study NCT02014584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
Study NCT02014584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dutasteride matching placebo will be supplied as capsules to be administered orally.
Study NCT03131882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: 1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
Study NCT03131882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
Study NCT00880646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oolong tea containing L-arabinose and indigestible dextrin
Study NCT00880646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oolong tea (Placebo)
Study NCT01046214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCl
Description: Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
Study NCT01046214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion HCl
Description: Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
Study NCT03845595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (LF-rTMS) group
Description: The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ \*rTMS\* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous \*FDI\* muscle, while the patient is contracting his whole limb as much as possible .
Study NCT03845595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
Study NCT01649024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT00955513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac diethylamine gel 2.32%
Description: diclofenac diethylamine gel 2.32% twice a day
Study NCT00955513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac diethylamine gel 2.32%
Description: diclofenac diethylamine gel 2.32% three times a day
Study NCT00955513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04716920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Attend Tai Chi exercise classes
Study NCT04716920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear FitBit
Study NCT04716920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Join Tai4Chijoint group
Study NCT04716920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04716920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01653236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Study NCT03462966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
Study NCT01653236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b
Study NCT01653236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Study NCT01653236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Study NCT01653236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Study NCT04692142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped classroom teaching method
Description: Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
Study NCT04692142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flipped classroom teaching method
Description: Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
Study NCT02239991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboelastometry
Description: Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
Study NCT01868555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study NCT01202058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEVO™ Sirolimus-eluting Coronary Stent System
Description: Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Study NCT01202058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)
Description: Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Study NCT01868555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 30
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study NCT01868555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 45
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days